Behind Biotech I Hong Tang on Traditional Chinese Medicine and Targeted Cancer Supportive Therapy
Hosted by Jingyi Liu August 3, 2022 Hong Tang Biography Dr. Hong Tang is Chief Medical Officer, and co-founder of OnQuality...
Newsroom
- Jun 30
Hopkins Biotech Podcast I Hong Tang: Targeting the Common Side Effects of Cancer Therapies
Hosted by Joe Varriale June 30, 2022 Hong Tang is the co-founder and Chief Medical Officer of OnQuality Pharmaceuticals, a targeted...
- Jun 15
Fierce Biotech I After 3 years away, BIO marked by first-time handshakes
Written by Max Bayer June 15, 2022 Six days after the World Health Organization officially declared COVID-19 a global pandemic on March...
- Jun 1
BioSpectrum Asia I Our approach to managing the side effects of cancer therapy has evolved
Source: https://www.biospectrumasia.com/e-magazine By Dr. Manbeena Chawla June 2022 Although there has been tremendous progress in...
- May 27
OnQuality Pharmaceuticals to Have Two Abstracts Published in the 2022 ASCO Annual Meeting Proceeding
View on PRNewswire - Preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment for...
- May 17
Podcast: Leading without the Title: Becoming a Natural Leader – with Hong Tang
Source: https://brilliancewithincoaching.com/podcast/leading-without-the-title-becoming-a-natural-leader-with-hong-tang/ Hong Tang is the...
- Mar 8
OnQuality Pharmaceuticals to Present Preclinical Data for OQL051, a Novel CID Therapeutic, at AACR
- OnQuality will present preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment...
- Mar 1
Informa I Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
High Hopes In COVID-19, Cancer, CNS, Immunology And Rare Disease By Eleanor Malone March 1, 2022 Executive Summary Evolving challenges...
- Feb 14
OnQuality Pharmaceuticals to Present NOVA-II Phase 2 Trial Update and Oncologist Survey at ASCO GU
- OnQuality will present an update on its NOVA-II Phase 2 clinical trial investigating OQL011, a proprietary ointment designed to treat...
- Feb 2
GEN | Supportive Care: OnQuality Treats Cancer’s Side Effects
Written by Alex Philippidis February 2, 2022 OnQuality recently announced positive news for its lead candidate OQL011, an ointment...